Semaglutide Dosing for a 40-Year-Old Woman
For weight management/obesity, start semaglutide subcutaneously at 0.25 mg once weekly, escalate monthly to 0.5 mg, then 1.0 mg, 1.7 mg, and finally 2.4 mg weekly as tolerated; for type 2 diabetes, start at 0.25 mg weekly and escalate to 0.5 mg or 1.0 mg weekly. 1, 2
Dosing Schedule
For Obesity/Weight Management
The FDA-approved titration schedule for subcutaneous semaglutide is 1:
- Weeks 1-4: 0.25 mg once weekly (starting dose)
- Weeks 5-8: 0.5 mg once weekly
- Weeks 9-12: 1.0 mg once weekly
- Weeks 13-16: 1.7 mg once weekly
- Week 17 onward: 2.4 mg once weekly (maintenance dose)
This monthly escalation schedule is critical for tolerability—it significantly reduces gastrointestinal side effects compared to faster titration 3. The 2.4 mg weekly dose achieved 16.9% weight loss at 68 weeks in the STEP 1 trial 1.
For Type 2 Diabetes
If treating diabetes rather than obesity 2:
- Weeks 1-4: 0.25 mg once weekly
- Week 5 onward: 0.5 mg once weekly (can remain here if adequate glycemic control)
- Optional escalation: Increase to 1.0 mg weekly after at least 4 weeks if additional glycemic control needed
Administration Details
- Inject subcutaneously in abdomen, thigh, or upper arm—absorption is equivalent across sites 2
- Can be given any day of the week; no evidence supports one day being superior 4
- If a dose is missed, administer within 5 days; if >5 days, skip and resume regular schedule
Oral Formulation Alternative
Oral semaglutide is FDA-approved for diabetes at 14 mg daily, with 25 mg and 50 mg doses showing efficacy for obesity in trials 1, 5. Critical: Must be taken in fasting state (overnight fast preferred) with ≤4 oz water, followed by 30-minute fast before eating—shorter fasting periods reduce absorption by 57-88% 6.
Side Effects
Gastrointestinal (Most Common)
The predominant side effects are gastrointestinal, occurring in 59-74% of patients 1, 7:
- Nausea (most common, typically transient)
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
Mitigation strategy: These are dose-dependent and ameliorated by the gradual monthly dose escalation 3. Most events are mild-to-moderate and resolve within weeks. Eating smaller meals and avoiding high-fat foods helps.
Serious Adverse Events
Pancreatitis: Monitor for severe abdominal pain radiating to the back. Discontinue if suspected 2.
Gallbladder disease: Rapid weight loss increases cholelithiasis risk. Watch for right upper quadrant pain 1.
Hypoglycemia: Risk increases when combined with insulin or sulfonylureas—may need to reduce doses of these medications 2.
Thyroid C-cell tumors: Black box warning based on rodent studies. Contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 2.
Acute kidney injury: Reported with severe gastrointestinal side effects causing dehydration. Ensure adequate hydration 2.
Diabetic retinopathy complications: Rapid glycemic improvement may temporarily worsen retinopathy in patients with pre-existing disease 2.
Rare but Documented
Agranulocytosis: One case report documented febrile neutropenia requiring G-CSF after several months of therapy 8. While causality remains uncertain (Naranjo score 3), consider baseline and periodic CBC monitoring in high-risk patients.
Discontinuation Rates
- 3-7% discontinue due to adverse events, primarily gastrointestinal 7, 9
- Side effects are the most common reason for discontinuation among those who stop treatment 10
Clinical Pearls
Dose flexibility: Real-world data shows many patients achieve satisfactory weight loss at 1.0 mg weekly without escalating to 2.4 mg 10. Consider maintaining at lower doses if patient achieves goals and tolerates well.
Cardiovascular benefits: Semaglutide 2.4 mg reduces major adverse cardiovascular events by 20% in patients with established CVD and obesity (SELECT trial) 1. The 1.0 mg dose reduced MACE by 26% in diabetic patients (SUSTAIN 6) 2.
Medication reductions: 24% of users report reduced/discontinued concomitant medications, especially antihypertensives and pain medications 10.
Avoid "counting clicks": 10% of users dose by pen clicks rather than following prescribed doses—this deviates from evidence-based dosing 10.
Pregnancy: Discontinue at least 2 months before planned pregnancy due to long half-life (approximately 1 week) 2.